

**BLISS GVS PHARMA LIMITED**

Regd. Office - 102, Hyde Park, Sakinaka Road, Andheri East- Mumbai-400072

**Statement of Unaudited Standalone and Consolidated Financial Results for the Quarter ended June 30, 2021**

(₹ in Lakh)

Sr. No	Particulars	Standalone				Consolidated			
		Quarter Ended		Year Ended		Quarter Ended		Year Ended	
		June 30, 2021	March 31, 2021	June 30, 2020	March 31, 2021	June 30, 2021	March 31, 2021	June 30, 2020	March 31, 2021
		Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited	Un-Audited	Audited
I	Revenue from Operations	13,303.05	10,523.24	11,401.88	46,551.31	16,814.54	13,205.34	12,955.00	57,720.54
II	Other Income	789.54	429.88	695.12	1,768.25	781.72	632.67	704.15	2,022.44
III	<b>Total Income (I+II)</b>	<b>14,092.59</b>	<b>10,953.12</b>	<b>12,097.00</b>	<b>48,319.56</b>	<b>17,596.26</b>	<b>13,838.01</b>	<b>13,659.15</b>	<b>59,742.98</b>
IV	<b>Expenses</b>								
a.	Cost of Materials consumed	7,228.50	6,228.92	3,738.06	21,565.36	8,312.65	7,149.45	4,410.56	25,980.84
b.	Purchase of Stock-in-Trade	215.78	470.22	3,129.37	4,649.73	1,384.46	1,323.00	3,650.72	8,097.56
c.	Changes in inventories of work in process, finished goods and stock in trade	(610.10)	(806.39)	69.32	(884.72)	(1,021.11)	(832.36)	(117.59)	(1,187.50)
d.	Employee Benefit Expense	1,538.22	1,599.53	1,409.14	5,860.93	1,773.97	1,898.49	1,603.23	6,809.21
e.	Finance Costs	130.05	201.24	151.99	419.39	139.86	236.24	182.77	551.37
f.	Depreciation and Amortisation Expense	348.13	340.35	342.88	1,376.22	433.41	426.85	428.65	1,722.96
g.	Other Expenses	2,337.58	1,511.75	1,215.55	6,213.98	2,904.43	1,978.19	1,460.36	7,355.84
	<b>Total Expenses</b>	<b>11,188.16</b>	<b>9,545.62</b>	<b>10,056.31</b>	<b>39,200.89</b>	<b>13,927.67</b>	<b>12,179.86</b>	<b>11,618.70</b>	<b>49,330.28</b>
V	<b>Profit / (Loss) before exceptional Items and tax (III-IV)</b>	<b>2,904.43</b>	<b>1,407.50</b>	<b>2,040.69</b>	<b>9,118.67</b>	<b>3,668.59</b>	<b>1,658.15</b>	<b>2,040.45</b>	<b>10,412.70</b>
VI	Exceptional Items	-	-	-	-	-	-	-	-
VII	<b>Profit / (Loss) before Tax (V-VI)</b>	<b>2,904.43</b>	<b>1,407.50</b>	<b>2,040.69</b>	<b>9,118.67</b>	<b>3,668.59</b>	<b>1,658.15</b>	<b>2,040.45</b>	<b>10,412.70</b>
VIII	<b>Tax Expense</b>								
i.	Current Tax	640.07	351.55	394.88	2,152.43	955.29	503.29	436.79	2,604.29
ii.	Deferred Tax Liability/(Asset)	98.56	40.54	(63.80)	116.89	98.79	51.65	(61.40)	123.29
iii.	Short/ Excess Provision of earlier years	-	99.27	-	99.27	1.37	287.96	-	287.96
IX	<b>Net Profit / (Loss) for the period</b>	<b>2,165.80</b>	<b>916.14</b>	<b>1,709.61</b>	<b>6,750.08</b>	<b>2,613.14</b>	<b>815.25</b>	<b>1,665.06</b>	<b>7,397.16</b>
X	<b>Other Comprehensive Income</b>								
i.	Items that will not be reclassified to profit & loss								
(i)	Remeasurement of the defined benefit liabilities/ (asset)	14.94	15.63	(45.99)	70.02	14.94	15.63	(45.99)	70.02
(ii)	Deferred tax on remeasurement of defined benefits liabilities/ (assets)	(3.76)	(3.93)	11.58	(17.62)	(3.76)	(3.93)	11.58	(17.62)
ii.	Items that will be reclassified to profit & loss								
(i)	Exchange differences in translating the financial statements of foreign operations	-	-	-	-	(110.23)	368.93	225.47	(138.56)
(ii)	Deferred tax relating to items that will be reclassified to profit or loss	-	-	-	-	27.74	(67.67)	(159.70)	34.87
XI	<b>Total Comprehensive Income for the period</b>	<b>2,176.98</b>	<b>927.84</b>	<b>1,675.20</b>	<b>6,802.48</b>	<b>2,541.83</b>	<b>1,128.21</b>	<b>1,696.42</b>	<b>7,345.87</b>
XII	<b>Profit/(Loss) attributable to :</b>								
i.	Owners of the Company	-	-	-	-	2,425.42	624.21	1,619.20	6,849.09
ii.	Non-controlling interests	-	-	-	-	187.72	191.04	45.86	548.07
XIII	<b>Other Comprehensive income attributable to :</b>								
i.	Owners of the Company	-	-	-	-	(73.63)	313.67	30.76	(53.07)
ii.	Non-controlling interests	-	-	-	-	2.32	(0.71)	0.60	1.78
XIV	<b>Total Comprehensive income attributable to :</b>								
i.	Owners of the Company	-	-	-	-	2,351.79	937.88	1,649.96	6,796.02
ii.	Non-controlling interests	-	-	-	-	190.04	190.33	46.46	549.85
XV	<b>Paid up equity share capital</b> ( Face Value - Re. 1/- each. )	1,033.57	1,031.47	1,031.47	1,031.47	1,033.57	1,031.47	1,031.47	1,031.47
XVI	<b>Earnings Per Share Basic &amp; Diluted (Not Annualised)</b>								
i.	Basic	2.10	0.89	1.66	6.54	2.35	0.61	1.57	6.64
ii.	Diluted	2.04	0.87	1.62	6.40	2.29	0.59	1.54	6.49



**Notes :**

- 1 The above results which are published in accordance with Regulation 33 of the SEBI (Listing Obligation & Disclosure Requirements), 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on July 31, 2021. The financial results are in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules in this regard.
- 2 The current quarter results have been subject to a limited review by the statutory auditors of the company. The statutory auditors, Kalyaniwalla & Mistry LLP have issued report with unmodified opinion on the standalone and consolidated financial results.
- 3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment information is disclosed.
- 4 The Group continues to monitor the impact of Covid - 19 on its business, including its impact on customers, supply-chain, employees and logistics. The Group doesn't expect any material impact on this account.
- 5 Employee Benefit Expenses includes Share Based Payment on account of ESOP Scheme, 2019 of ₹ 148.16 Lakhs (Previous Period ₹ 243.01) as per Ind AS 102 for quarter ended June 30, 2021.
- 6 During the quarter ended June 30, 2021, the company has allotted 2,10,500 equity shares of ₹ 1 each fully paid, on exercise of stock options by employees in accordance with the company's ESOP scheme, 2019. From the total number of options granted 34,91,000, the outstanding number of options as at June 30, 2021 are 26,40,500 including 1,44,000 shares for which application money is received pending allotment.
- 7 The figures for the quarter ended March 31, 2021 are the balancing figures between audited figures in respect of the full financial year ended March 31, 2021 and the year to date published result for the nine months ended December 31, 2020.

Place : Mumbai  
Date : July 31, 2021



For BLISS GVS PHARMA LIMITED  
  
Gagan Harsh Sharma  
Managing Director  
Din No : 07939421



## | Key Highlights for Standalone FY 2021-22 Q1 (June'2021)

FY 2021-22 Q1 (June'2021)		FY 2020-21 Q1 (June'2020)
<b>Revenue from Operation</b> <u>₹ 13,303.05 Lakhs</u>	↑ 16%	<b>Revenue from Operation</b> <u>₹ 11,401.88 Lakhs</u>
<b>EBITDA</b> <u>₹ 2,593.07 Lakhs</u> 19%	↑ 41%	<b>EBITDA</b> <u>₹ 1,840.44 Lakhs</u> 15%
<b>Other Income</b> <u>₹ 789.54 Lakhs</u>	↑ 14%	<b>Other Income</b> <u>₹ 695.12 Lakhs</u>
<b>PBT</b> <u>₹ 2,904.43 Lakhs</u> 21%	↑ 42%	<b>PBT</b> <u>₹ 2,040.69 Lakhs</u> 17%
<b>PAT</b> <u>₹ 2,165.80 Lakhs</u> 15%	↑ 27%	<b>PAT</b> <u>₹ 1,709.61 Lakhs</u> 14%

## | Key Highlights for Consolidated FY 2021-22 Q1 (June'2021)

FY 2021-22 Q1 (June'2021)		FY 2020-21 Q1 (June'2020)
<b>Revenue from Operation</b> <u>₹ 16,814.54 Lakhs</u>	↑ 30%	<b>Revenue from Operation</b> <u>₹ 12,955.00 Lakhs</u>
<b>EBITDA</b> <u>₹ 3,460.14 Lakhs</u> 21%	↑ 78%	<b>EBITDA</b> <u>₹ 1,947.72 Lakhs</u> 15%
<b>Other Income</b> <u>₹ 781.72 Lakhs</u>	↑ 11%	<b>Other Income</b> <u>₹ 704.15 Lakhs</u>
<b>PBT</b> <u>₹ 3,668.59 Lakhs</u> 21%	↑ 80%	<b>PBT</b> <u>₹ 2,040.45 Lakhs</u> 15%
<b>PAT</b> <u>₹ 2,613.14 Lakhs</u> 15%	↑ 57%	<b>PAT</b> <u>₹ 1,665.06 Lakhs</u> 12%

# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,  
The Board of Directors,  
Bliss GVS Pharma Limited,  
102, Hyde Park,  
Saki Vihar Road,  
Andheri (East),  
Mumbai 400 072.

## LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Bliss GVS Pharma Limited** ("the Company"), for the quarter ended June 30, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited Financial Results prepared in accordance with the applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

5. We draw attention to our reliance on the management representation in respect of the recoverability of the company's investment in, loans given, Interest accrued and Trade receivable to one of its subsidiary and its step-down subsidiary aggregating to Rs. 4,636.97 Lakh.

Our opinion is not modified in respect of this matter.

**For KALYANIWALLA & MISTRY LLP  
CHARTERED ACCOUNTANTS  
Firm Registration No. 104607W/W100166**

*D. Sai*

**Sai Venkata Ramana Damarla  
Partner**

**Membership No. 107017**

**UDIN: 21107017AAAA CC 7950**

Place: Mumbai

Dated: July 31, 2021.



# KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

To,  
The Board of Directors,  
Bliss GVS Pharma Limited,  
102, Hyde Park,  
Saki Vihar Road,  
Andheri (East),  
Mumbai -400 072.

## LIMITED REVIEW REPORT

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of **Bliss GVS Pharma Limited** (“the Parent”) and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended June 30, 2021 (“the Statement”), attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“the Listing Regulations”).
2. This Statement, which is the responsibility of the Parent’s Management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the financial results of the following entities:

### A. Incorporated in India:

1. Kremoint Pharma Private Limited, India
- 1.1. Eipii Exports Private Limited, India



LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001  
TEL.: (91) (22) 6158 6200, 6158 7200 FAX : (91) (22) 6158 6275

**B. Incorporated outside India:**

2. Bliss GVS International Pte. Ltd., Singapore
    - 2.1. Greenlife Bliss Healthcare Limited, Nigeria
  3. Bliss GVS Clinic Healthcare Pte. Ltd., Singapore
  4. Asterisk Lifesciences Limited (UK), United Kingdom
    - 4.1. Asterisk Lifesciences (GH) Limited, Ghana
5. Based on our review and procedures conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the financial statements of 7 subsidiaries included in the statement, whose financial results reflect the Group's share for the quarter ended June 30, 2021 for the under mentioned items. These financial statements and other financial information have been reviewed by other auditors whose reports have been furnished to us by the management, and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries and to the extent, they have been derived from such financial statements is based on the report of such other auditors.

(In Lakh)

Particulars	Quarter Ended June 30, 2021
Total Revenue	3,511.49
Profit After Tax	447.34
Total Comprehensive Income	364.85

Our conclusion on the Statement is not modified in respect of the above matter.

**For KALYANIWALLA AND MISTRY LLP  
CHARTERED ACCOUNTANTS  
Firm Registration No. 104607W/W100166**

*Sai*

**Sai Venkata Ramana Damarla  
Partner**

**Membership No. 107017**

**UDIN: 21107017AAAACD2447**

Place: Mumbai,

Dated: July 31, 2021.

